Kukadzi 2024: Tumor-infiltrating lymphocyte (TIL) kurapwa kurapwa inzira inogoneka iyo inoshandisa immune system yemuviri kurwisa mamota akasimba. Iyi nzvimbo yekurapa muChina iri kufambira mberi nekukurumidza nekuda kwekudyara kuri kuita nyika mukurapa masero uye mabhizinesi ekugadzirisa magene, kunyangwe vachiri vadiki. Kurapa kweTIL kuChina kunosangana nematambudziko akadai sekushaikwa kwezvivakwa, kusavapo kwemaprotocol akamiswa, uye kusanzwisisa kwakakwana kwekusarudzwa kwevarwere uye kusanganiswa kwekurapa. Kubuda kwechimeric antigen receptor (CAR) -T sero kurapwa muChina yakasimudzira nharaunda yakanaka yekufambisira mberi kweTIL kurapwa, kusimudzira kushandira pamwe pakati pemasangano nemafemu akazvimirira.
Kufambira mberi uye Kushandiswa
Dr. Steven Rosenberg vakabudirira kurapa mbeva dzembeva ne autologous TILs mukupera kwema1980, pavakatanga kugadzirwa. TIL kurapa. Since then, TIL therapy has advanced substantially, showing great effectiveness in specific solid tumors, especially melanoma, cervical cancer, and colorectal cancer.
Unogona kuda kuverenga: CAR T-Cell Therapy muChina
Clinical Trials and Progress
Grit Biotechnology, headquartered in Shanghai, secured $60 million in Series B funding to advance the development of its TIL candidates, with a primary emphasis on melanoma, cervical, and kenza yemapapu. Kuedza uku kunoenderana nepasirese mapatani muTIL therapy, iyo inowanzobatanidza marapirwo akasanganiswa nemamwe ma immunotherapies, senge immune cheki inovharira mishonga.
Recent studies have emphasized that the composition and location of TILs within tumors are crucial factors affecting prognosis and treatment results. Comprehending the intricate relationships between TILs and the tumarara microenvironment is crucial for enhancing TIL therapy tailored to specific tumor types and refining patient categorization.
Zvirongwa Zvenguva Yemberi
Zvinhu zvakati wandei zvinoda kutariswa kuti ushandise zvizere kugona kwe TIL kurapwa muChina.
Kumira: Kumisikidzwa kunosanganisira kugadzira zvibvumirano zveTIL kuzviparadzanisa nevamwe, kukura, uye kuendesa kubvumira kuenzanisa kuri nyore pakati pezvidzidzo zvekiriniki uye kuwedzera kunzwisiswa kwemhedzisiro yekuedzwa.
Kusarudzwa kwevarwere: Kugadzira yakasimba biomarker mapaneru ekusarudza nekuvimbika varwere vanozobatsirwa neTIL kurapwa kwakakosha pakugovanisa zviwanikwa uye nekuwedzera kurapa kwakanaka.
Kubatana: Kukurudzira kushandira pamwe pakati pezvikoro zvedzidzo, zvipatara, uye vanodyidzana navo mumaindasitiri vanosimudzira hunyanzvi uye nekuchimbidza kududzira kwehunyanzvi hweTIL kurapa mukuita kwekiriniki.
Dzidzo: Inopa zvirongwa zvekudzidzisa zvakagadzirirwa uye zviwanikwa zvekudzidzisa zvevashandi vehutano vanoita basa TIL kurapa ichawedzera maitiro akanaka uye kuwedzera ruzivo rwekufambira mberi kwazvino munzvimbo.
Unogona kuda kuverenga: CAR T Sero kurapwa kweyakawanda myeloma muChina
Kuwedzera kutarisisa pakutsvagisa uye dzidzo muChina kuchatsigira kufambiswa kweTIL kurapwa kwemamota akasimba nekusimudzira hunyanzvi uye kugadzira marapirwo akachengeteka uye anoshanda.
Ndeipi mamiriro azvino e tumor infiltrating lymphocyte therapy muChina?
Tumor-infiltrating lymphocyte (TIL) therapy is still at an advanced stage in China. According to recent rumors, the US Food and Drug Administration may provide approval to employ TIL treatment to treat some cancers. It has great promise for treating solid cancers. Using chimeric antigen receptor (CAR)-T cells for treatment has sped up the growth of TIL therapy in China, making it easier for companies that work in cell therapy and gene editing to do well.
Hunhu hwakakosha hwekurapwa kweTIL muChina ndeiyi:
• Zvigadzirwa zvishoma uye maprotocol akatsanangurwa
• Focus on melanoma, cervical, and kenza yakajeka
• Kudyidzana nemasangano epasi rose nemakambani akazvimirira
• Zvirongwa zvedzidzo zvevanachiremba
Nepo kurapwa kweTIL kwakaratidza budiriro inoshamisa mumhando dzebundu chairo, kuita kwayo kunoramba kwakaoma nekuda kwezvinhu zvakaita segoho rakaderera reTIL, kushomeka kweTIL kushingirira mushure mekuisirwa, uye matambudziko mukugadzira mapuroteni anowirirana.
Mikana yeramangwana yekurapwa kweTIL muChina inosanganisira:
• Yakamisikidzwa TIL yekuzviparadzanisa nevamwe, kuwedzera, uye manejimendi ekutonga
• Kuvandudza kusarudzwa kwevarwere uye kusanganiswa kwekurapa
• Kushandira pamwe kwakavandudzwa pakati pevadzidzisi, zvipatara, nevadyidzani vemaindasitiri
• Zvishandiso zvedzidzo zvakawedzera zvevanopa utano
Matanho aya anovavarira kuwedzera kushandiswa kweTIL kurapwa muChina, zvichizotungamira kune yakachengeteka uye inoshanda yakasimba marapirwo emarara.
Ndedzipi mhando dzegomarara dzinonyanya kurapwa neTIL therapy?
Mhando dzakawanda dzekenza dzinorapwa ne tumor-infiltrating lymphocyte (TIL) therapy ndeidzi:
Melanoma: Kurapa kweTIL kunoshanda mukurapa melanoma, rudzi rwegomarara reganda.
Cervical cancer: TIL therapy has shown promising outcomes in cervical cancer patients, resulting in tumor reduction and increased survival rates.
Colorectal cancer: Kurapwa kweTIL kwakaratidza kubudirira kwekutanga muvarwere vegomarara remukati, zvichiratidza mukana werudzi urwu rwegomarara.
Ipo kurapwa kweTIL kuchiri munhanho dzekutanga muChina, kuenderera mberi nekutsvagisa uye zvidzidzo zvekiriniki zviri kuongorora mashandisirwo azvo mumamota mazhinji akasimba, zvichiratidza kuchinjika uye kuvimbisa kushandiswa kwakawanda mune ramangwana.
Mutengo weTIL kurapwa muChina
TIL kurapwa iri mumatanho ekuyedzwa parizvino, uye yakazara mutengo weTIL kurapwa muChina unogona kubva pakati pemadhora makumi matanhatu nemakumi matanhatu nemakumi mashanu emadhora. CAR T Cell kurapwa mutengo muChina iri pakati pe$45,000 ne$80,000 USD. Mutengo weTIL kurapwa unogona kusiyana zvichienderana nehurongwa hwekurapa, chipatara, uye zvimwe zvinhu. Zvinokurudzirwa kuonana nemupi wehutano kana chipatara muChina kuti uwane rumwe ruzivo nezve mutengo weTIL kurapwa.
